Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units | Zendy

Juliana F. Roos | Zendy; Jürgen B. Bulitta | Zendy; Jeffrey Lipman | Zendy; Carl M. J. Kirkpatrick | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units

Author(s) -

Juliana F. Roos,

Jürgen B. Bulitta,

Jeffrey Lipman,

Carl M. J. Kirkpatrick

Publication year - 2006

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkl349

Subject(s) - cefepime , dosing , pharmacodynamics , pharmacokinetics , medicine , intensive care , intensive care medicine , pharmacology , antibiotics , biology , imipenem , microbiology and biotechnology , antibiotic resistance

(i) To develop a population pharmacokinetics (PK) model for cefepime in patients in intensive care units (ICUs). (ii) To assess the pharmacokinetic-pharmacodynamic profile of various cefepime dosing regimens and to assess their expected probability of target attainment (=PTA expectation value) against common ICU pathogens such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research